Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
Crossref DOI link: https://doi.org/10.1007/s00415-016-8182-4
Published Online: 2016-06-17
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Newsome, Scott D.
Kieseier, Bernd C.
Arnold, Douglas L.
Shang, Shulian
Liu, Shifang
Hung, Serena
Sabatella, Guido
Funding for this research was provided by:
Biogen
License valid from 2016-06-17